The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment
We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.PMID:38555033 | DOI:10.1016/j.drudis.2024.103967 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Anna Carolina Machado Marinho Alexander Chapeaurouge Brunheld Maia Dutra Barbara Cibelle S F Quintela Soraya S Pereira Carla Freire C Fernandes Source Type: research
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Drug Discov Today. 2024 Mar 28:103974. doi: 10.1016/j.drudis.2024.103974. Online ahead of print.ABSTRACTAccumulation of misfolded proteins and protein aggregates leading to degeneration of neurons is a hallmark of several neurodegenerative diseases. Therapy mostly relies on symptomatic relief. Immunotherapy offers a promising approach for the development of disease-modifying routes. Such strategies have shown remarkable results in oncology, and this promise is increasingly being realized for neurodegenerative diseases in advanced preclinical and clinical studies. This review highlights cases of passive and active immunothe...
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Abhiyanta Mukherjee Soumojit Biswas Ipsita Roy Source Type: research
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment
We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.PMID:38555033 | DOI:10.1016/j.drudis.2024.103967 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Anna Carolina Machado Marinho Alexander Chapeaurouge Brunheld Maia Dutra Barbara Cibelle S F Quintela Soraya S Pereira Carla Freire C Fernandes Source Type: research
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Drug Discov Today. 2024 Mar 28:103974. doi: 10.1016/j.drudis.2024.103974. Online ahead of print.ABSTRACTAccumulation of misfolded proteins and protein aggregates leading to degeneration of neurons is a hallmark of several neurodegenerative diseases. Therapy mostly relies on symptomatic relief. Immunotherapy offers a promising approach for the development of disease-modifying routes. Such strategies have shown remarkable results in oncology, and this promise is increasingly being realized for neurodegenerative diseases in advanced preclinical and clinical studies. This review highlights cases of passive and active immunothe...
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Abhiyanta Mukherjee Soumojit Biswas Ipsita Roy Source Type: research
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment
We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.PMID:38555033 | DOI:10.1016/j.drudis.2024.103967 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Anna Carolina Machado Marinho Alexander Chapeaurouge Brunheld Maia Dutra Barbara Cibelle S F Quintela Soraya S Pereira Carla Freire C Fernandes Source Type: research
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Drug Discov Today. 2024 Mar 28:103974. doi: 10.1016/j.drudis.2024.103974. Online ahead of print.ABSTRACTAccumulation of misfolded proteins and protein aggregates leading to degeneration of neurons is a hallmark of several neurodegenerative diseases. Therapy mostly relies on symptomatic relief. Immunotherapy offers a promising approach for the development of disease-modifying routes. Such strategies have shown remarkable results in oncology, and this promise is increasingly being realized for neurodegenerative diseases in advanced preclinical and clinical studies. This review highlights cases of passive and active immunothe...
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Abhiyanta Mukherjee Soumojit Biswas Ipsita Roy Source Type: research
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment
We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.PMID:38555033 | DOI:10.1016/j.drudis.2024.103967 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Anna Carolina Machado Marinho Alexander Chapeaurouge Brunheld Maia Dutra Barbara Cibelle S F Quintela Soraya S Pereira Carla Freire C Fernandes Source Type: research
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Drug Discov Today. 2024 Mar 28:103974. doi: 10.1016/j.drudis.2024.103974. Online ahead of print.ABSTRACTAccumulation of misfolded proteins and protein aggregates leading to degeneration of neurons is a hallmark of several neurodegenerative diseases. Therapy mostly relies on symptomatic relief. Immunotherapy offers a promising approach for the development of disease-modifying routes. Such strategies have shown remarkable results in oncology, and this promise is increasingly being realized for neurodegenerative diseases in advanced preclinical and clinical studies. This review highlights cases of passive and active immunothe...
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Abhiyanta Mukherjee Soumojit Biswas Ipsita Roy Source Type: research
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment
We present an overview of current antivenom therapy in the context of sdAb development for toxin neutralization. Furthermore, strategies are presented for identifying snake venom's major toxins as well as for developing antisnake toxin sdAbs by employing proteomic tools for toxin neutralization.PMID:38555033 | DOI:10.1016/j.drudis.2024.103967 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 30, 2024 Category: Drugs & Pharmacology Authors: Anna Carolina Machado Marinho Alexander Chapeaurouge Brunheld Maia Dutra Barbara Cibelle S F Quintela Soraya S Pereira Carla Freire C Fernandes Source Type: research
2023 in review: FDA approvals of new medicines
Drug Discov Today. 2024 Mar 27:103966. doi: 10.1016/j.drudis.2024.103966. Online ahead of print.ABSTRACTAn analysis of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 68 {AuQ: Should this be 69 as shown in Figure 1A&B?} new entities in the year 2023, 50 % more than in the previous year. Oncology drugs tied with congenital and infectious diseases drugs for the most approvals. Although orphan and priority approvals continued at a high pace, the rate of fast-track approvals continued to decline. The ...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Michael S Kinch Zachary Kraft Tyler Schwartz Source Type: research
Enzyme-responsive design combined with photodynamic therapy for cancer treatment
Drug Discov Today. 2024 Mar 27:103965. doi: 10.1016/j.drudis.2024.103965. Online ahead of print.ABSTRACTPhotodynamic therapy (PDT) is a noninvasive cancer treatment that has garnered significant attention in recent years. However, its application is still hampered by certain limitations, such as the hydrophobicity and low targeting of photosensitizers (PSs) and the hypoxia of the tumor microenvironment. Nevertheless, the fusion of enzyme-responsive drugs with PDT offers novel solutions to overcome these challenges. Utilizing the attributes of enzyme-responsive drugs, PDT can deliver PSs to the target site and selectively r...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Siying Zhi Meixin Huang Kui Cheng Source Type: research
Physical and mechanical properties of ocular thin films: a systematic review and meta-analysis
Drug Discov Today. 2024 Mar 27:103964. doi: 10.1016/j.drudis.2024.103964. Online ahead of print.ABSTRACTThe ocular thin film presents a potential solution for addressing challenges to ocular drug delivery. In this review, we summarise the findings of a comprehensive review analysing 336 formulations from 68 studies. We investigated the physical and mechanical properties of ocular thin films, categorised into natural polymer-based, synthetic polymer-based, and combined polymer films. The results showed that the type of polymers used impacted mucoadhesion force, moisture absorption:moisture loss ratio, pH, swelling index, an...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Mitra Farahmandnejad Shohre Alipour Ali Nokhodchi Source Type: research
2023 in review: FDA approvals of new medicines
Drug Discov Today. 2024 Mar 27:103966. doi: 10.1016/j.drudis.2024.103966. Online ahead of print.ABSTRACTAn analysis of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 68 {AuQ: Should this be 69 as shown in Figure 1A&B?} new entities in the year 2023, 50 % more than in the previous year. Oncology drugs tied with congenital and infectious diseases drugs for the most approvals. Although orphan and priority approvals continued at a high pace, the rate of fast-track approvals continued to decline. The ...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Michael S Kinch Zachary Kraft Tyler Schwartz Source Type: research
Enzyme-responsive design combined with photodynamic therapy for cancer treatment
Drug Discov Today. 2024 Mar 27:103965. doi: 10.1016/j.drudis.2024.103965. Online ahead of print.ABSTRACTPhotodynamic therapy (PDT) is a noninvasive cancer treatment that has garnered significant attention in recent years. However, its application is still hampered by certain limitations, such as the hydrophobicity and low targeting of photosensitizers (PSs) and the hypoxia of the tumor microenvironment. Nevertheless, the fusion of enzyme-responsive drugs with PDT offers novel solutions to overcome these challenges. Utilizing the attributes of enzyme-responsive drugs, PDT can deliver PSs to the target site and selectively r...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Siying Zhi Meixin Huang Kui Cheng Source Type: research
Physical and mechanical properties of ocular thin films: a systematic review and meta-analysis
Drug Discov Today. 2024 Mar 27:103964. doi: 10.1016/j.drudis.2024.103964. Online ahead of print.ABSTRACTThe ocular thin film presents a potential solution for addressing challenges to ocular drug delivery. In this review, we summarise the findings of a comprehensive review analysing 336 formulations from 68 studies. We investigated the physical and mechanical properties of ocular thin films, categorised into natural polymer-based, synthetic polymer-based, and combined polymer films. The results showed that the type of polymers used impacted mucoadhesion force, moisture absorption:moisture loss ratio, pH, swelling index, an...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Mitra Farahmandnejad Shohre Alipour Ali Nokhodchi Source Type: research
